The Inflation Reduction Act and Ibrutinib

1. CMS announced a 38% price reduction for ibrutinib, effective 2026. 2. Negotiations initiated under the Inflation Reduction Act. 3. Factors for pricing included drug market history and costs. 4. Concerns exist regarding patient access and innovation impacts. 5. ibrutinib is considered a blockbuster with $24 billion in sales from 2017-2020. 6. New BTK inhibitors are seen as alternatives to ibrutinib. 7. Negotiation process lacks transparency.